Metabolism of N-methyl, N-propargylphenylethylamine: Studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes

Cellular and Molecular Neurobiology

Volumn 27, Issue 2, 2007, Pages 179-190

  Rittenbach, Katherine A ^a   Holt, Andrew ^a   Ling, Lei ^b   Shan, Jackie ^b   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CV Technologies Inc   (Canada)

Author keywords

( ) deprenyl; CYP enzymes; Human liver microsomes; Metabolism; N methyl,N propargylphenylethylamine (MPPE)

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; ETHYLAMINE; N METHYL N PROPARGYLPHENYLETHYLAMINE; N METHYLPHENETHYLAMINE; N PROPARGYLPHENYLETHYLAMINE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ARTICLE; CATABOLISM; CATALYSIS; DEMETHYLATION; DRUG METABOLISM; ELECTRON CAPTURE DETECTION; GAS CHROMATOGRAPHY; HUMAN; LABORATORY TEST; LIVER MICROSOME METABOLISM; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCREENING;

ARYL HYDROCARBON HYDROXYLASES; BINDING, COMPETITIVE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NEUROPROTECTIVE AGENTS; OXIDOREDUCTASES, N-DEMETHYLATING; SELEGILINE;

EID: 33847281902     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10571-006-9085-1     Document Type: Article

References (39)

1. Am, O. B., Amit, T., and Youdim, M. B. H. (2004). Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355:169-172.
2. Berry, M. D., Juorio, A. V., and Paterson, I. A. (1994). Possible mechanisms of action of (?)-deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. 44:141-161.
3. Birks, J., and Flicker, L. (2003). Selegiline for Alzheimer's disease. Cochrane Database System Review. CD000442.
4. DeLaGarza, V. W. (2003). Pharmacologic treatment of Alzheimer's disease: An update. Am. Fam. Phys. 68:1365-1372.
5. Desta, Z., Zhao, X., Shin, J. G., and Flockhart, D. A. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-958.
6. Ebadi, M., Sharma, S., Shavali, S., and El Refaey, H. (2002). Neuroprotective actions of selegiline. J. Neurosci. Res. 67:285-289.
7. Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., and Lindley, C. M. (2000). Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28:1222-1230.
8. Grace, J. M., Kinter, M. T., and Macdonald, T. L. (1994). Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha- dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7:286-290.
9. Harvey, A. T., and Preskorn, S. H. (1996). Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors: Part 1. J. Clin. Psychopharmacol. 16:273-285.
10. Heinonen, E. H., and Myllyla, V. (1998). Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Safety. 19:11-22.
11. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., and Greenblatt, D. J. (2000). CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab. Dispos. 28:1176-1183.
12. Hidestrand, M., Oscarson, M., Salonen, J. S., Nyman, L., Pelkonen, O., Turpeinen, M., and Ingelman-Sundberg, M. (2001). CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos. 29:1480-1484.
13. Kennedy, S. H., Lam, R. W., Cohen, N. L., Ravindran, A. V., and Group, T. C. D. W. (2001). Clinical guidelines for the treatment of depression disorders: IV. Medications and other biological treatments. Can. J. Psychiatry 46:38S-58S.
14. Kwan, E., Baker, G. B., Shuaib, A., Ling, L., and Todd, K. G. (2000). N-Methyl,N-propargyl-2-phenylethylamine (MPPE), an analog of deprenyl, increases neuronal cell survival in thiamin deficiency encephalopathy. Drug Dev. Res. 51:244-252.
15. Lei, L., Sloley, B. D., Urichuk, L., Chan, J., and Baker, G. B. (in preparation). Novel analogues of deprenyl: Ability to inhibit MAO and protect against DSP-4-induced depletion of hippocampal noradrenaline.
16. Magyar, K., and Szende, B. (2004). (?)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neuro. Toxicol. 25:233-242.
17. Mandel, S., Grunblatt, E., Riederer, P., Gerlach, M., Levites, Y., and Youdim, M. B. (2003). Neuroprotective strategies in Parkinson's disease: An update on progress. CNS Drugs 17:729-762.
18. Maruyama, W., and Naoi, M. (1999). Neuroprotection by (?)-deprenyl and related compounds. Mech. Ageing Dev. 111:189-200.
19. Morita, S., Shimoda, K., Someya, T., Yoshimura, Y., Kamijima, K., and Kato, N. (2000). Steadystate plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J. Clin. Psychopharmacol. 20:141-149.
20. Mytilineou, C., Leonardi, E. K., Radcliffe, P., Heinonen, E. H., Han, S. K., Werner, P., Cohen, G., and Olanow, C. W. (1998). Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J. Pharmacol. Exp. Ther. 284:700-706.
21. Mytilineou, C., Radcliffe, P. M., and Olanow, C. W. (1997). L-(?)-Desmethylselegiline, a metabolite of selegiline [L-(?)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J. Neurochem. 68:434-436.
22. Nemeroff, C. B., DeVane, C. L., and Pollock, B. G. (1996). Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153:311-320.
23. Paterson, I. A., Zhang, D., Warrington, R. C., and Boulton, A. A. (1998). R-deprenyl and R-2-heptyl-Nmethylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J. Neurochem. 70:515-523.
24. Riederer, P., and Lachenmayer, L. (2003). Selegiline's neuroprotective capacity revisited. J. Neural. Transm. 110:1273-1278.
25. Ring, B. J., and Wrighton, S. A. (2000). Industrial viewpoint: Application on in vitro drug metabolism in various phases of drug development. In Levy, R. H., Thummel, K. E., Trager, W. F., Hansten, P. D., and Eichelbaum, M. (eds.), Metabolic Drug Interactions, Lippincott Williams & Wilkins, Philadelphia, pp. 29-40.
26. Rittenbach, K., and Baker, G. B. (submitted). Involvement of cytochrome P450 2D6, 2B6 and 2C19 in the metabolism of (?)-deprenyl and N-methyl,N-propargylphenylethylamine.
27. Rittenbach, K., Sloley, B. D., Ling, L., Coutts, R. T., Shan, J., and Baker, G. B. (2005). A rapid, sensitive electron-capture gas chromatographic procedure for analysis of metabolites of N-methyl, N- propargylphenylethylamine, a potential neuroprotective agent. J. Pharmacol. Toxicol. Methods 52:373-378.
28. Salonen, J. S., Nyman, L., Boobis, A. R., Edwards, R. J., Watts, P., Lake, B. G., Price, R. J., Renwick, A. B., Gomez-Lechon, M.-J., Castell, J. V., Ingelman-Sundberg, M., Hidestrand, M., Guillouzo, A., Corcos, L., Goldfarb, P. S., Lewis, D. F. V., Taavitsainen, P., and Pelkonen, O. (2003). Comparative studies on the cytochrome P450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos. 31:1093-1102.
29. Salsali, M., Coutts, R. T., and Baker, G. B. (2000). A rapid electron-capture gas chromatographic procedure for the analysis of p-hydroxymephenytoin. J. Pharmacol. Toxicol. Methods 44:461-465.
30. Semkova, I., Wolz, P., Schilling, M., and Krieglstein, J. (1996). Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 315:19-30.
31. Sowa, B. N., Todd, K. G., Tanay, V. A. M. I., Holt, A., and Baker, G. B. (2004). Amine oxidase inhibitors and development of neuroprotective drugs. Curr. Neuropharmacol. 2:153-168.
32. Stocchi, F., and Olanow, C. W. (2003). Neuroprotection in Parkinson's disease: Clinical trials. Ann. Neurol. 53(Suppl 3):S87-97; discussion S97-89.
33. Taavitsainen, P., Anttila, M., Nyman, L., Karnani, H., Salonen, J. S., and Pelkonen, O. (2000). Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol. Toxicol. 86:215-221.
34. Tatton, W. G. (1993). Selegiline can mediate neuronal rescue rather than neuronal protection. Move. Disord. 8(Suppl 1):S20-S30.
35. Tatton, W. G., and Chalmers-Redman, R. M. (1996). Modulation of gene expression rather than monoamine oxidase inhibition: (?)-Deprenyl-related compounds in controlling neurodegeneration. Neurology 47:S171-S183.
36. Tatton, W. G., Chalmers-Redman, R. M., Elstner, M., Leesch, W., Jagodzinski, F. B., Stupak, D. P., Sugrue, M. M., and Tatton, N. A. (2000). Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J. Neural. Transm. Suppl.:77-100.
37. Thummel, K. E., Kunze, K. L., and Shen, D. D. (2000). Metabolically-based drug-drug interactions: Principles and mechanisms. In Levy, R. H., Thummel, K. E.. Trager, W. F., Hansten, P. D., and Eichelbaum, M. (eds.), Metabolic Drug Interactions, Lippincott Williams & Wilkins, Philadelphia, pp. 3-21.
38. Todd, K. G., and Butterworth, R. F. (1998). Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency. J. Neurosci. Res. 52:240-246.
39. Venkatakrishnan, K., von Moltke, L. L., and Greenblatt, D. J. (1999). Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): Implications for interactions with enzyme-inducing drugs. J. Clin. Pharmacol. 39:567-577.